3.92

0.76% -0.04

Recursion Pharmaceuticals Inc (RXRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RXRX? Forum Prognose

Schlusskurs vom Vortag:

$3.96

Offen:

$3.95

24-Stunden-Volumen:

17.73M

Relative Volume:

1.03

Marktkapitalisierung:

$2.08B

Einnahmen:

$66.41M

Nettoeinkommen (Verlust:

$-559.78M

KGV:

-3.2607

EPS:

-1.2022

Netto-Cashflow:

$-328.09M

1W Leistung:

+7.08%

1M Leistung:

+18.55%

6M Leistung:

-19.14%

1J Leistung:

-20.28%

1-Tages-Spanne:

$3.81

$4.05

1-Wochen-Bereich:

$3.61

$4.09

52-Wochen-Spanne:

$2.77

$7.18

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Firmenname

Recursion Pharmaceuticals Inc

Sektor

Healthcare (1100)

Branche

Biotechnology (615)

Telefon

(385) 269-0203

Adresse

41S RIO GRANDE STREET, SALT LAKE CITY

Mitarbeiter

600

Twitter

Nächster Verdiensttermin

2026-08-04

Neueste SEC-Einreichungen

RXRX's Discussions on Twitter

Compare RXRX vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RXRX Recursion Pharmaceuticals Inc	3.92	2.02B	66.41M	-559.78M	-328.09M	-1.2022
VRTX Vertex Pharmaceuticals Inc	524.24	134.02B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.87	68.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	921.42	58.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	320.37	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	191.67	40.23B	742.00K	-1.37B	-1.07B	-7.0731

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-17	Hochstufung	JP Morgan	Neutral → Overweight
2025-07-03	Fortgesetzt	Morgan Stanley	Equal-Weight
2023-05-22	Eingeleitet	Morgan Stanley	Equal-Weight
2023-03-16	Eingeleitet	Needham	Buy
2022-09-16	Eingeleitet	KeyBanc Capital Markets	Overweight
2022-04-18	Herabstufung	BofA Securities	Buy → Neutral
2022-03-04	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-09-21	Eingeleitet	Berenberg	Buy
2021-05-11	Eingeleitet	BofA Securities	Buy
2021-05-11	Eingeleitet	Goldman	Neutral
2021-05-11	Eingeleitet	JP Morgan	Neutral
2021-05-11	Eingeleitet	KeyBanc Capital Markets	Overweight
2021-05-11	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten

Jul 06, 2026

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo

Jul 06, 2026

Recursion Pharmaceuticals (NASDAQ:RXRX) stock gains as short interest and Russell flows hit AI-biotech rally - TechStock²

Jul 06, 2026

Form 144 RECURSION PHARMACEUTICALS For: 6 July By Investing.com - Investing.com Canada

Jul 06, 2026

Insider sells 340,440 RXRX shares (NASDAQ: RXRX) - Stock Titan

Jul 06, 2026

Jul 05, 2026

Recursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base – Has The Bull Case Changed? - Yahoo Finance UK

Jul 05, 2026

Recursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes - Yahoo Finance

Jul 05, 2026

Recursion Pharmaceuticals (NASDAQ:RXRX) beats out biotech funds as filings, spending become focus - TechStock²

Jul 05, 2026

Recursion Pharmaceuticals Stock (RXRX) Opinions on Technical Consolidation - Quiver Quantitative

Jul 05, 2026

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool

Jul 05, 2026

Recursion Pharmaceuticals director Blake Borgeson sells $105,600 in stock - Investing.com

Jul 05, 2026

Jul 04, 2026

Recursion Pharmaceuticals director Blake Borgeson sells $105,600 in stock By Investing.com - Investing.com UK

Jul 04, 2026

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? - The Globe and Mail

Jul 04, 2026

Jul 03, 2026

RXRX rallies past biotech ETFs as short interest, insider-sale filings shape coming week - TechStock²

Jul 03, 2026

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? - The Motley Fool

Jul 03, 2026

Jul 02, 2026

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain - Moomoo

Jul 02, 2026

RXRXRecursion Pharmaceuticals Inc Volatility & Greeks - Finviz

Jul 02, 2026

Recursion Pharmaceuticals (NASDAQ:RXRX) pops, short interest still much bigger than new founder-sale alert - TechStock²

Jul 02, 2026

Form 4 Recursion Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada

Jul 02, 2026

Recursion Pharmaceuticals (RXRX) director granted 5,109 Class A shares - Stock Titan

Jul 02, 2026

Recursion (NASDAQ: RXRX) director Dean Y. Li receives 3,747-share equity grant - Stock Titan

Jul 02, 2026

RXRX Stock Draws ARK Buying As AI Drug Story Builds - timothysykes.com

Jul 02, 2026

Christopher C. Gibson lists multiple Class A sales (RXRX) - Stock Titan

Jul 02, 2026

Jul 01, 2026

Form 144 RECURSION PHARMACEUTICALS For: 1 July By Investing.com - Investing.com Canada

Jul 01, 2026

RXRX (NASDAQ: RXRX) insider sale notice — 100,000 Class A shares - Stock Titan

Jul 01, 2026

RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits

Jul 01, 2026

Jun 30, 2026

Anthropic Launches Claude Science to Enter Life Sciences, AI Drug Discovery Stocks Tumble in Response - NAI500

Jun 30, 2026

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Jun 30, 2026

Jun 29, 2026

Does Recursion (RXRX) Russell Value Index Lift Recast Its AI Biotech Story as Deep Value? - simplywall.st

Jun 29, 2026

Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Recursion Pharmaceuticals Stock (RXRX) Opinions on ARK Invest's Recent Share Purchase - Moomoo

Jun 28, 2026

Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 3000E Value Benchmark - marketscreener.com

Jun 28, 2026

Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 3000 Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Enterprise value to EBITDA forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView

Jun 27, 2026

Jun 26, 2026

Recursion Pharmaceuticals (RXRX) ascends while market falls: Some facts to note - MSN

Jun 26, 2026

RXRX Stock Gains Attention As ARK Investment Steps In - timothysykes.com

Jun 26, 2026

Recursion Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:RXRX) - TradingView

Jun 26, 2026

Recursion Pharmaceuticals Stock Short Interest Rises to 36.75% - Quiver Quantitative

Jun 26, 2026

8RL Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Cathie Wood's investment moves on June 25! Added over 890,000 shares of Recursion Pharmaceuticals in a major purchase, while selling more than 170,000 shares of Alibaba - Moomoo

Jun 26, 2026

Did Recursion Pharmaceuticals' Q4 Beat Signal a Turning Point - Kavout | AI

Jun 26, 2026

2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying - The Globe and Mail

Jun 26, 2026

Jun 25, 2026

Enterprise value to EBIT forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView

Jun 25, 2026

Recursion Pharmaceuticals (RXRX) Short Interest & Short Float | Updated Jun 2026 $RXRX - MarketBeat

Jun 25, 2026

Why Could (NASDAQ:RXRX) Stay on Nasdaq Composite Radar? - Kalkine Media

Jun 25, 2026

Jun 24, 2026

Recursion Pharmaceuticals (RXRX) Sees Bulk Purchase from ARK Inv - GuruFocus

Jun 24, 2026

Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance

Jun 24, 2026

Recursion Pharmaceuticals (RXRX) Q4 2025 earnings summary - Quartr

Jun 24, 2026

Jun 23, 2026

1 of the Most Interesting AI Stocks in the Market Isn’t a Tech Company - Yahoo Finance

Jun 23, 2026